BUT－6010的抗肿瘤活性实验研究

目的研究BUT-6010对肿瘤的抑制作用。方法体外抗肿瘤实验：选取9种人源肿瘤细胞株，并将其分为BUT-6010组、顺铂阳性对照组、细胞对照组和培养基空白对照组，MTS法测定抑制率和IC50值；体内抗肿瘤实验：实验分为BUT-6010 10mg／kg组、BUT-6010 20mg／kg组、BUT-6010 30mg／kg组、顺铂阳性对照组（2．5mg／kg）和模型组。通过对S180荷瘤小鼠瘤重的研究，观察BUT-6010的体内抗肿瘤作用。结果BUT-6010对9种人癌细胞株的IC50均小于顺铂。顺铂（2．5mg／kg）的抑瘤率达51．8％（P〈0．05），BUT-6010（30mg／kg）抑瘤率为52．8％（P〈0．05）。结论BUT-6010（30mg／kg）的安全性与有效性同顺铂（2．5mg/kg）相当。

Experimental study of anti-tumor activity of BUT-6010

Objective To study the acute toxicities and anti-tumor activity of BUT-6010.Methods Anti-tumor experiment in vitro was that: nine human cancer cell lines were divided into BUT-6010 group,Cisplatin positive control group,cell control group and culture medium blank group.The inhibition rate and IC50 were studied by MTS assay;anti-tumor experiment in vivo was that: the study was divided into BUT-6010 of 10 mg/kg group,BUT-6010 of 20 mg/kg group,BUT-6010 of 30 mg/kg group,Cisplatin positive control group(2.5 mg/kg) and model group.The anti-tumor activity of BUT-6010 in vivo was observed by studying the S180 tumor-bearing mice.Results The IC50 of BUT-6010 in nine human cancer cell lines was lower than that of Cisplatin.The inhibition rate of Cisplatin(2.5 mg/kg) was 51.8%(P < 0.05),the inhibition rate of BUT-6010(30 mg/kg) was 52.8%(P < 0.05).Conclusion The safety and efficacy of BUT-6010(30 mg/kg) is the same as Cisplatin(2.5 mg/kg).